Linked Life Data

16204011

Source:http://linkedlifedata.com/resource/pubmed/id/16204011

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
31
pubmed:dateCreated
2005-10-31
pubmed:abstractText
Most cases of non-small-cell lung cancer (NSCLC) with dramatic responses to gefitinib have specific activating mutations in the epidermal growth factor receptor (EGFR), but the predictive value of these mutations has not been defined in large clinical trials. The goal of this study was to determine the contribution of molecular alterations in EGFR to response and survival within the phase II (IDEAL) and phase III (INTACT) trials of gefitinib.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0732-183X
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
23
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
8081-92
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:16204011-Adult, pubmed-meshheading:16204011-Aged, pubmed-meshheading:16204011-Antineoplastic Agents, pubmed-meshheading:16204011-Carcinoma, Non-Small-Cell Lung, pubmed-meshheading:16204011-Female, pubmed-meshheading:16204011-Gene Amplification, pubmed-meshheading:16204011-Gene Expression Regulation, Neoplastic, pubmed-meshheading:16204011-Humans, pubmed-meshheading:16204011-Lung Neoplasms, pubmed-meshheading:16204011-Male, pubmed-meshheading:16204011-Middle Aged, pubmed-meshheading:16204011-Mutation, pubmed-meshheading:16204011-Quinazolines, pubmed-meshheading:16204011-Receptor, Epidermal Growth Factor, pubmed-meshheading:16204011-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:16204011-Sequence Analysis, DNA, pubmed-meshheading:16204011-Survival Rate, pubmed-meshheading:16204011-Tumor Markers, Biological
pubmed:year
2005
pubmed:articleTitle
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
pubmed:affiliation
Massachusetts General Hospital Cancer Center and Department of Pathology, Harvard Medical School, Charlestown, MA 02129, USA.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't, Clinical Trial, Phase II, Clinical Trial, Phase III, Research Support, N.I.H., Extramural